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background:  To achieve the target blood pressure recommended by the latest guidelines, multiple antihypertensive drugs are needed in most 
patients. Furthermore, recent studies showed that central aortic pressure is closely associated with target organ damages. We compared the effects 
of a direct rennin inhibitor and a diuretic when used in combination with angiotensin II receptor blocker on central aortic blood pressure (BP) in 
hypertensive patients.
methods: The ALEA study was a 24-week, prospective, multicenter, randomized, open-label study. Inclusion criteria were hypertensive patients with 
a clinic BP ≥140 mm Hg and/or 90 mm Hg and already being treated with valsartan only. A total of 103 patients were enrolled from 15 institutions 
from Jun 2012 to March 2013. We administered aliskiren (150-300 mg/day) to 52 patients or triochlorothiazide (TCM) (0.5-2 mg/day) to 51 
patients in addition to the valsartan (80 mg/day) and followed for 24 weeks. Central BP was measured by radial artery tonometory (HEM9000AI, 
Omron, Japan). The Primary outcome measure was a change in central aortic BP from baseline to the end of follow-up. Secondary efficacy measures 
included differences in changes in microalbuminuria from the baseline to the follow-up.
results: In both groups, brachial systolic BPs were significantly decreased 24 weeks later, and the difference in the reduction in brachial systolic 
BP between the groups was not significant (1.9 mm Hg; 95% CI: -5.3 to 9.1 mm Hg; P=0.61). After adjustment for baseline covariates, the extent 
of the reduction in central BP in the aliskiren/valsartan group was similar to that in the TCM/valsartan group (the between-group difference was 
3.7 mm Hg; 95% CI: -5.8 to 13.1 mm Hg; P=0.44). The Urine Albumin-to-Creatinine Ratio (UACR) showed a significantly greater reduction for the 
aliskiren/valsartan combination than for the TCM/valsartan combination (7.2 mg/gCr; 95% CI: 0.56 to 13.78 mg/gCr; P=0.03) after adjustment for 
covariates.
conclusion: The combination of valsartan and aliskiren had a comparable effect on central systolic BP, but a greater effect on UACR compared to 
the combination of valsartan and TCM.
